08 nov: Cargotec's Kalmar provides XVELA collaborative stowage solution t..
08 nov: P.A.M. Transportation Services, Inc. Announces Preliminary Result..
08-11-2017 15:01:38

Zealand Pharma: Interim report for the first nine months of 2017

Relateret indhold
22 jan - 
Aktier/middag: Bavarian Nordic topper i rødt C25
22 jan - 
Aktier/åbning: Genmab topper positivt C25 efter flere n..
22 jan - 
Aktier/tendens: Genmab kan tage fokus i forventet nervø..
Relateret debat
19:00 - 
Jeg følger med. Det der køb og salg som vinden blæser, ..
18:12 - 
Synes du gir den lige lovligt meget som politi mand. Du..
17:34 - 
Jeg anser ikke alpes streger for spam, men derimod de 9..

Company announcement - No. 50/2017

Interim report for the first nine months of 2017

Copenhagen, November 8, 2017 - Zealand Pharma A/S ("ZEAL") announces financial results and continued strong progress for its product candidates and business for the first nine months of 2017. Financial guidance for 2017 has been revised with 4-6% lower operating expenses.

Financial results for the first nine months of 2017

  • Revenue of DKK 128.5 million/USD 20.4 million[1] (DKK 54.3 million/USD 8.1 million2 in the first nine months of 2016).
  • Net operating expenses3 of DKK 251.7 million/USD 39.9 million1 (DKK 220.9 million/USD 33.1 million2 in the first nine months of 2016).
  • Net result of DKK -162.3 million/USD -25.7 million1 (DKK -206.7 million/USD -31.0 million2 in the first nine months of 2016).
  • Cash position of DKK 780.6 million/USD 123.8 million1 per September 30, 2017 (December 31, 2016: DKK 642.1 million/USD 91.0 million4, including restricted cash).

Business highlights for Q3 2017

  • Listing on the Nasdaq Global Select Market in the U.S. raising gross DKK 567 million/USD 90 million[1].
  • Initiation of Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.
  • Orphan drug designation for dasiglucagon for the treatment of congenital hyperinsulinism was granted by FDA in the U.S.
  • Boehringer Ingelheim initiated Phase 1 trial in the amylin analog program, triggering a EUR 4 million milestone payment to Zealand.
  • Boehringer Ingelheim initiated Phase 1 trial in the GLP-1/glucagon dual agonist program.
  • Soliqua® 100/33 revenue increased 37% and payer coverage increased 4%-point over the previous quarter to cover 65% of commercial lives.

Business highlights for the period thereafter

  • Orphan drug designation for glepaglutide for the treatment of short bowel syndrome granted by FDA in the U.S.
  • The potential for less than once-daily dosing with glepaglutide is being evaluated in a clinical trial, following positive results in the Phase 2 trial for Short Bowel Syndrome.
  • Patient enrolment completed for Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.

Britt Meelby Jensen, President and CEO of Zealand

, comments:

"We continue to see strong results and progress with our clinical product candidates, and following the U.S. IPO in August, where we raised USD 90 million, we are in a solid position to advance our late stage clinical programs at full speed. For glepaglutide, we are in preparation to start Phase 3 mid-2018, we received orphan drug designation and we are finalizing a trial to assess the potential for a better dosing option for patients. In addition, two of our partnered programs have advanced to Phase 1 for treatment of obesity and/or diabetes. With this, I am convinced that Zealand is set for a successful future."

Revised financial guidance for 2017 

For 2017, Zealand maintains its revenue guidance of a continued increase in royalty payments from Sanofi. No specific guidance on the level of royalties can be provided as Sanofi has not provided any guidance on expected 2017 sales.

Milestone revenue of DKK 101 million has been received from partners.

Net operating expenses in 2017 are expected to be within the range of DKK 375-385 million, 4-6 % lower than previously guided (DKK 390-410 million). The decrease relates to timing of clinical studies as well as tight cost control.

Operating loss before royalty income/expenses has been reduced from DKK 290-310 million to DKK 275-285 million.

Conference call today at 4 pm CET/10 am EST

Zealand's management will be hosting a conference call today at 4 pm CET/10 am EST to present the results for the first nine months of 2017. Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and Executive Vice President and Chief Medical and Development Officer Adam Steensberg. The presentation will be followed by a Q&A session.

The dial-in numbers are:

DK standard access             +45 32711658

UK and international            +44 (0) 20 3427 1907

U.S. (free dial-in)                 +1 646 254 3366

Passcode                            3321181

A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/m6/p/wr84wf2d also accessible on the Investor section of Zealand's website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the start. A recording of the event will be made available on the Investor section of Zealand's website after the call.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

[1] Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.30 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2017.

2 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.68 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2016.

3 Net operating expenses consist of research, development and administrative expenses less other operating income.

4 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 7.05 per USD 1.00, which was the rounded official exchange rate of such currencies at December 31, 2016.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/c335bc3e-baed-4c37-a6b9-4a9afa57572a

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13:51
ZEAL
ja og en ting mere er helt sikkert... der kommer ingen kommentarer fra dig i de Zeal tråde med posit..
7
08:18
ZEAL
Published: 08:16 CET 23-01-2018 /GlobeNewswire /Source: Zealand Pharma / : ZEAL /ISIN: DK0060257814 ..
7
20 jan
ZEAL
Godt at se at de kan hoppe direkte i fase 3 og ikke skal køre kombineret fase 2-3 studie. Det betyde..
6
19 jan
ZEAL
Published: 23:30 CET 19-01-2018 /GlobeNewswire /Source: Zealand Pharma / : ZEAL /ISIN: DK0060257814 ..
5
13:08
ZEAL
Denne nyhed er dukket op de sidste par dage og det er helt korrekt fra Alpe's side at link den. Den ..
4
22 jan
ZEAL
Danske Bank har en elller flere kunder der vil  købe min 25.000 stk aktier i Zealand - det kan være ..
4
21 jan
ZEAL
Sidste uge sluttede med at der efter US lukke tid kom accept fra FDA til direkte at gå i fase 3 med ..
4
17:25
ZEAL
sådan set er det ret så fantastisk1. ungee har i mange år læst diverse TAeres indlæg og kommentarer ..
3
22 jan
ZEAL
hvem siger, at de er tilfældige. Det er vist bare noget du finder på, fordi du ikke ved hvad de lave..
3
16:07
ZEAL
99/100 er indenfor rækkevidde, med aktuelle købssignaler, som target på en IHS     https://invst.ly/..
2

Torm/Jyske: Regnskabstal afslører lav pris for aktien

23-01-2018 16:21:15
Jyske Bank har set nærmere på rederiet Torm, og nu sænker banken kursmålet et nøk til 68 kr. fra 72 kr.Banken har dog fortsat et positivt syn på aktien, der fortsat får anbefalingen "køb".Med Torms regnskabsopdatering, der blev præsenteret sammen med planerne om skibskøb og en kapitaludvidelse sent mandag, bliver den lave pris for Torm åbenbar, vurderer Jyske Bank.Den øgede likviditet i aktien, so..

Mærsk/Sydbank: Drilling-salg er realistisk - ikke nødvendigvis elegant

23-01-2018 13:17:37
Det giver fin mening, at A.P. Møller Holding sammen med en ukendt industripartner skulle være tæt på at købe borerigselskabet Maersk Drilling af A.P. Møller-Mærsk.Ifølge Berlingske Business, der har talt med flere anonyme kilder, skulle handlen have en værdi af over 27 mia. kr.- Til trods for stigende oliepriser er drilling stadig et presset marked. Der er ingen af Mærsks konkurrenter, der har pen..

Aktier/åbning: Tryg går til bunds i positivt marked - Mærsk stiger

23-01-2018 09:24:18
Tryg halter tirsdag morgen lidt efter det generelle marked, efter at forsikringskoncernen har skudt regnskabssæsonen ind med tal for fjerde kvartal, der peger i flere retninger.Målt på det forsikringstekniske resultat slog Tryg akkurat analytikerforventningerne. Til gengæld haltede bundlinjen lidt efter forventningerne blandt andet som følge af en lidt skuffende investeringsafkast. Også bruttopræm..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab: Partner melder om vækst i Darzalex-salg på 86 pct.
2
Danske Bank/RBC: Konsensus for udlodninger efter 2018 er for høje
3
Aktier/middag: Salgsrygter sender Mærsk til tops i positivt marked
4
Mærsk/Sydbank: Drilling-salg er realistisk - ikke nødvendigvis elegant
5
Aktier/åbning: Tryg går til bunds i positivt marked - Mærsk stiger

Relaterede aktiekurser

Zealand Pharma A/S 95,30 4,2% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. januar 2018 20:59:51
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180122.2 - EUROWEB2 - 2018-01-23 20:59:51 - 2018-01-23 20:59:51 - 1 - Website: OKAY